FindTrial
Sign In

BGB-3111

DRUG4 trials

Sponsors

BeiGene, Tianjin Medical University Cancer Institute and Hospital

Conditions

Healthy VolunteersMCLWaldenström's Macroglobulinemia

Phase 1

A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects
CompletedNCT03432884
BeiGeneHealthy Volunteers
Start: 2018-01-25End: 2018-04-16Updated: 2020-04-24
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males
CompletedNCT04163783
BeiGeneHealthy Volunteers
Start: 2017-03-29End: 2017-04-18Updated: 2019-11-15

Phase 2

Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients
RecruitingNCT06463691
Tianjin Medical University Cancer Institute and HospitalMCL
Start: 2024-08-01End: 2029-07-31Target: 30Updated: 2025-05-11

Phase 3

A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)
CompletedNCT03053440
BeiGeneWaldenström's Macroglobulinemia
Start: 2017-01-25End: 2022-06-21Updated: 2024-10-26

Related Papers

Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study.
2025-12-01
Trium study: Exploring MRD-guided triplet therapy with sonrotoclax, zanubrutinib, and CD20mab in Untreated Mantle Cell Lymphoma: A prospective, multicenter, Phase II Study
Blood2025-11-03
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
Blood Advances2024-12-036 citations
Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study
Blood2024-11-054 citations
Comparison of Zanubrutinib and Ibrutinib As Treatments for Waldenstrom Macroglobulinemia: A Real-World Retrospective Study
Blood2024-11-05
Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)
Blood2024-11-05
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial
Future Oncology2024-07-294 citations
Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib
Blood Advances2024-03-1915 citations
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
Blood Advances2024-02-0524 citations
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor (BTKi) Zanubrutinib in Patients with Waldenström Macroglobulinemia (WM)
Blood2023-11-021 citations
Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study ≥1 Year After Transitioning to Zanubrutinib
Blood2023-11-021 citations
P1679: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) TREATED WITH ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR): RESULTS FROM THE PHASE 3 ASPEN TRIAL LONG-TERM FOLLOW-UP
HemaSphere2023-08-011 citations
Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States
eJHaem2023-01-115 citations
Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.
2022-06-236 citations
ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM).
Journal of Clinical Oncology2022-06-0115 citations
P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)
HemaSphere2022-06-017 citations
Zanubrutinib for the Treatment of B-cell Malignancies
touchREVIEWS in Oncology & Haematology2022-01-011 citations
Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenström macroglobulinemia in the United States.
Journal of Clinical Oncology2021-05-206 citations
Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström macroglobulinemia (WM): Matching-adjusted indirect comparisons.
Journal of Clinical Oncology2021-05-201 citations
ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM).
Journal of Clinical Oncology2020-05-2013 citations

3 more papers not shown